NEW YORK – Ambry Genetics and Caris Life Sciences today announced a partnership on cancer genetic testing in the US.
Under the terms of the agreement, Caris will offer Ambry's 67-gene CancerNext-Expanded gene panel to evaluate hereditary risk of cancer alongside its Caris Molecular Intelligence tumor profiling.
Financial and other terms of the partnership were not disclosed.